Research
Hormonal
Leptin analogs (metreleptin) are effective for treating obesity only in patients with generalized lipodystrophy or congenital leptin deficiency, but are ineffective and contraindicated for general diet-based obesity due to leptin resistance.
Leptin analogs like metreleptin are not for general weight loss. They are reserved for rare genetic conditions like generalized lipodystrophy where the body cannot produce leptin. For most people with obesity, leptin levels are already high, and adding more does not help.
GoodQualifiesHIGH confidence
Metreleptin is contraindicated in patients with general, nongenetic obesity that does not result from internal leptin defects... The challenge and non-effectiveness of leptin therapy approach in obesity management is that plasma levels of leptin are already higher than in lean ones, suggesting leptin resistance
Why this rating
Based on FDA approval and specific clinical indications.
Source
Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges
Skyler Brandfon et al. · Cureus · 2023
DOI 10.7759/cureus.46623
narrative_reviewCited 38×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide 2.4 mg/week and liraglutide 3 mg/day) produce significant weight loss in adults with obesity or overweight with comorbidities by delaying gastric emptying and increasing satiety, with semaglutide demonstrating superior efficacy compared to liraglutide.Good
- MC4R agonists (setmelanotide) are effective for treating obesity in individuals with specific genetic deficiencies (POMC, PCSK1, LEPR) or Bardet-Biedl syndrome, but are not approved for general obesity.Good
- Lipase inhibitors (orlistat and cetilistat) reduce weight by inhibiting fat absorption, but are associated with gastrointestinal side effects and are less effective in patients with diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →